# A Double Blind Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Frovatriptan in the Acute Treatment of Migraine

> **NCT00821483** · PHASE3 · COMPLETED · sponsor: **SK Chemicals Co., Ltd.** · enrollment: 298 (actual)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** Frovatriptan

## Key facts

- **NCT ID:** NCT00821483
- **Lead sponsor:** SK Chemicals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2008-02
- **Final completion:** 2008-02
- **Target enrollment:** 298 (ACTUAL)
- **Last updated:** 2013-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00821483

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00821483, "A Double Blind Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Frovatriptan in the Acute Treatment of Migraine". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00821483. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*